Not rendering correctly? View this email as a web page here.
            
TNAC-DEC23-News

 


Hello Colleague,

Please find the second edition of the Monthly Infectious Diseases Summary; our subjective look at the most important news of the month. Please let us know how you like it and if there is something interesting we missed by contacting at this email address. 

 
Global Salmonella Strathcona Outbreak Likely Linked to Tomatoes- 149 Cases Across 11 Countries
Article
 

Salmonella VirusA multistate outbreak of Salmonella Strathcona has been reported in 11 countries, including Austria, Finland, Czechia, Denmark, France, Germany, Italy, Luxembourg, Norway, the United Kingdom, and the United States. As of November 13, 2023, a total of 149 cases have been documented, with no significant gender-based differences across various age groups. The outbreak spans from January to November, with the majority of cases reported between August and October.

Cases in the EU/EEA and the UK revealed a pattern of recent travel to various countries, including Croatia, Italy, Montenegro, Egypt, and unspecified European destinations. In the US, six cases reported travel to Europe, specifically Spain, Italy, Croatia, France, and Slovenia, with Italy being a common destination for 4 out of 6 cases. The strain responsible, Salmonella Strathcona, has a history of outbreaks, including a 2011 incident in Denmark linked to 'datterino' tomatoes. Subsequent outbreaks occurred in Denmark and Germany in 2019 and 2020. Genetic analysis shows a clonal nature of the strain, with a shared genetic cluster observed in isolates from 2011 to 2023. Among the 2023 cases, 61.5% reported consuming fresh tomatoes before the onset of the disease, while 48% reported egg consumption, and 46% reported cheese consumption. The European Centre for Disease Prevention and Control (ECDC) assesses this as a re-emerging, seasonal outbreak, likely linked to tomatoes, but further investigation is required to confirm this hypothesis. Continue reading...

See our salmonella products here.

 
Heat-Driven Dengue Crisis in Jamaica Sparks Urgent Call for Advanced Diagnostics
Article
 

In the summer of 2023, small island developing states (Sids) faced 103 health-threatening heat days annually, intensifying the risks of heat-related illnesses and diseases like dengue fever. Jamaica's recent dengue outbreak, influenced by the amplified impact of climate change, unfolded amidst optimal conditions for mosquito proliferation following drought and extreme weather fluctuations. Declared in September 2023, the outbreak led to over 3,100 cases and nine deaths by November, straining Jamaica's healthcare system. The broader vulnerability of Sids to climate change, encompassing extreme weather events and rising sea levels, accentuates the urgent need for global action. As record-breaking heat events become more frequent, the article serves as a call to action for governments and health organizations to prioritize the development and deployment of cutting-edge diagnostic technologies. Continue reading...

See all our Flavivirus products here and do not hesitate to enquire about the pricing of our best-selling Dengue VLPs, perfect for the development of next-generation diagnostic assays!

TNAC_DEC-DENV-2-1
Figure 1. Negative staining electron microscopy of DENV2 virus-like particles (a) and non-reducing SDS-PAGE gel showing purified Dengue virus serotype 2 virus-like particles (b); envelope protein at approx. 55kDa, prM protein running at approx. 18kDa and M protein at approx. 10kDa.

 

 

Mpox, Quietly Circulated Among Humans for Over 5 Years, Sparking a Global Emergency in 2022

Article
 

Mpox VirusThe disease formerly known as monkeypox, now called mpox, circulated in humans for over five years before the 2022 global outbreak, according to research. The virus, initially discovered in monkeys in the 1950s, transitioned to humans in 1970. While earlier human cases were linked to rodent contact in endemic areas, the 2022 outbreak revealed an unexpected number of mutations, suggesting sustained human transmission since 2016. The B.1 lineage drove the global outbreak, with declining cases due to targeted public health measures. However, diverse lineages persist in countries like the UK and the US, originating from Nigeria, indicating the ongoing human epidemic.

“Any new or nascent outbreak may have potential to go global. We need to focus on detecting outbreaks even when case numbers are low and find a way of stamping it out before it establishes in the human population.” said Dr Áine O’Toole, an evolutionary biologist at the University of Edinburgh. Continue reading... 

Have a look at our full range of Mpox products here and at the paper APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016.

 
Looming measles outbreak in English schools
Article
 

Measles VirusThe Royal College of Paediatrics and Child Health (RCPCH) has updated guidance on managing children with viral respiratory tract infections in the UK, incorporating measles symptoms due to recent outbreaks. With poor vaccination coverage among children under 5, the lowest in a decade, is growing concern. The RCPCH recommends immediate isolation and testing, wearing protective gear for unimmunized children showing measles symptoms. Current outbreaks have showed 49 cases so far, in comparison to the 54 cases in the whole 2022. Only 72% of children under 5 are fully vaccinated with two doses of the measles, mumps, and rubella vaccine, well below the World Health Organization’s target of 95%, hence the RCPCH calls for a prompt national vaccination strategy publication, addressing accessibility, misinformation, and disparities. Camilla Kingdon, RCPCH president said: ‘We are already starting to see the effects of this with measles outbreaks occurring in London, Wales, and Leicester,” describing the need for “disappointing but necessary” guidance update. Continue reading...

See our full range of Measles products here and have a look at our blog: Virus-like particles – the new candidate of choice for diagnosing and preventing rubella.

 
Meet Our Team
Richard White, Business Development Manager
 

 

RichardWhite_Portrait

 

Richard White, an employee at The Native Antigen Company, has a breadth of knowledge in life sciences business development. Richard writes:

I was born in Springfield, Massachusetts and educated in the Philadelphia area (Temple University and Lincoln University) and Arizona (Arizona State University) and completed my postdoctoral training at the Mayo Medical Center (Rochester, MN).

My career is blend of commercial areas that include Sales/ Business Development/Marketing and Account management across three main sectors: Diagnostics (FDA regulated, CE mark)-assays, pharmaceutical marketing and sales, genetics, and genomics in Oncology in strategic marketing.

Over the past two decades, I have worked for large pharmaceutical companies like Eli Lilly, Novartis, and AstraZeneca as well as Roche Diagnostics and Roche Molecular in New Product Planning, Strategic and Tactical Marketing roles. Also, I served in roles with Foundation Medicine and Genomic Health that increased my awareness and acumen in the genetic and genomic testing business as I pursued by large matrix organizations.

I led a sales team for Eli Lilly in the Neuroscience Division and was fortunate to Achieve the President’s Council Award and had the pleasure of launching several products into the psychiatric marketplace (Zyprexa IM and Zydis, Cymbalta and Strattera). The team was successful in increasing the penetration of these products in the VA and hospital system in the Washington, DC area and transitioning from sales executives to marketing and market access position within Eli Lilly.

What do I bring to the Native Antigen Company?

My commercial acumen in the IVD and CE regions expanded dramatically when I joined Roche Diagnostics as an entry point to diagnostics and led a team of Product and Marketing Managers to support IVD and CE products for Cobas' Taqman system on a global basis.

In my role as Business development Manager for North and South America, I strive to bring my commercial experience to bear to help established and new customers understand the unique value position of our company.

We are expanding rapidly and progressively by seeking to build the Native Antigen brand by engaging customers across several channels in these regions. The customers we work with are very diverse and have very specific needs and require an ability to be flexible and often with urgency, tight timelines so responsiveness is key.

 
Resources you might have missed...
Resources
 

 

The Native Antigen Company- Top Pharma Outsourcing Award

We keep our content up to date so that you can stay in touch with the news and resources that are the latest and greatest for everything "Antibodies and Antigens." Check out the latest:


 

Clearance Sale

Sale

The Native Antigen Company is pleased to announce our biggest sale ever, up to 80% off selected lines of products. All the items on sale exhibit the same high quality as our full-price products. With only a few last vials available for some of the products on the list, you do not want to wait, contact us today! 

New call-to-action

FooterBar_WhiteonTeal_1700x400